There are currently 98 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
NCT04368039
Recruiting
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Gender:
ALL
Ages:
Between 15 years and 35 years
Trial Updated:
10/28/2024
Locations: Harding Hospital, Columbus, Ohio
Conditions: Psychosis, Schizophrenia, First-episode Psychosis
Register for Updates
CAE for Poorly Adherent Individuals with Schizophrenia
NCT06061952
Recruiting
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Schizophrenia
Register for Updates
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05304767
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/26/2025
Locations: Alea Research, Phoenix, Arizona +172 locations
Conditions: Schizophrenia
Register for Updates
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: North County Clinical Research, Oceanside, California +11 locations
Conditions: Schizophrenia
Register for Updates
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
NCT05658510
Recruiting
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2025
Locations: BioXcel Clinical Research Site 113, Bellflower, California +23 locations
Conditions: Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Register for Updates
ITEST: Introspective Accuracy As a Novel Target for Functioning in Psychotic Disorders
NCT05899348
Recruiting
People with psychotic disorders experience a high level of functional disability, and a major contributor to this disability is introspective accuracy, which is defined as inaccurate judgements of one's abilities and performance on tasks. Yet, no intervention has directly targeted introspective accuracy for psychotic illnesses. This trial will evaluate a new intervention, called iTEST, that uses mobile devices to train people with psychotic disorders to improve introspective accuracy and, ultima... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/24/2025
Locations: University of California, San Diego, La Jolla, California +1 locations
Conditions: Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
Register for Updates
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212
Recruiting
This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/24/2025
Locations: Clinical Research Site # 145, Bentonville, Arkansas +10 locations
Conditions: Schizophrenia
Register for Updates
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
NCT05838560
Recruiting
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/24/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Schizophrenia, Treatment Resistant Depression, Aging, Premature
Register for Updates
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
NCT00001246
Recruiting
Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the name implies, magnetism to create pictures with excellent anatomical resolution. Functional MRIs are diagnostic tests that allow doctors to not only view anatomy, but physiology and function. It is for these reasons that MRIs are excellent methods for studying the brain. In this study, researchers will use MRI to assess brain anatomy and function in X and Y chromosome variation... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
03/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder
Register for Updates
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
NCT06315283
Recruiting
The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia. Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with ora... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/17/2025
Locations: Teva Investigational Site 15739, Los Alamitos, California +8 locations
Conditions: Schizophrenia
Register for Updates
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
NCT05208190
Recruiting
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/13/2025
Locations: University of California, Los Angeles, Los Angeles, California +6 locations
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
Tolerability of MDMA in Schizophrenia
NCT05770375
Recruiting
Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness. Whereas many symptoms of schizophrenia can be treated with antipsychotic medications, deficits in social motivation persist, leading to significant social disability in patients. There is currently no effective treatment for this symptom of the illness. One promising and unexplored avenue to enhance social motivation in schizophrenia is ± 3,4-... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/13/2025
Locations: UCLA, Los Angeles, California
Conditions: Schizophrenia
Register for Updates